In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rise In Securities Class Action Filings In Life Sciences Sector

Executive Summary

Last year proved to be another record period for securities class actions, with a 13% increase in cases filed compared with 2018, and a 24% increase in claims brought against life sciences companies compared with 2018, according to a report by Cornerstone Research: Securities Class Action Filings: 2019 Year In Review.

You may also be interested in...



QUOTED. Harel Gadot.

Medtech Insight talked with XACT Robotics’ executive chairman Harel Gadot about plans for the FDA-cleared ACE robotic system and market opportunities. See what Gadot said about the market opportunity here. 

Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria

Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round. 

NeuroMetrix Gets FDA De Novo Authorization For Neuromodulation Device To Treat Fibromyalgia

NeuroMetrix plans to market the prescription-based Quell in the fourth quarter to US rheumatologists and pain medicine physicians.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel